Sudeep Pharma Ltd
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
- Market Cap ₹ 6,422 Cr.
- Current Price ₹ 569
- High / Low ₹ 796 / 562
- Stock P/E 47.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 35.6 %
- ROE 32.8 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 50.4% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 123 | 215 | 343 | 459 | 502 | |
| 98 | 171 | 276 | 277 | 311 | |
| Operating Profit | 25 | 44 | 67 | 182 | 191 |
| OPM % | 21% | 20% | 20% | 40% | 38% |
| 3 | 3 | 7 | 6 | 9 | |
| Interest | 1 | 1 | 2 | 5 | 7 |
| Depreciation | 3 | 4 | 5 | 9 | 11 |
| Profit before tax | 25 | 43 | 69 | 175 | 183 |
| Tax % | 27% | 22% | 27% | 24% | 24% |
| 18 | 33 | 50 | 133 | 139 | |
| EPS in Rs | 128.02 | 236.60 | 356.04 | 945.36 | 14.27 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 14% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 50% |
| 3 Years: | 40% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 | 10 |
| Reserves | 80 | 113 | 162 | 355 | 481 | 715 |
| 20 | 31 | 84 | 78 | 140 | 143 | |
| 30 | 67 | 97 | 80 | 86 | 121 | |
| Total Liabilities | 131 | 213 | 344 | 514 | 717 | 988 |
| 60 | 68 | 137 | 180 | 189 | 299 | |
| CWIP | 8 | 24 | 8 | 45 | 88 | 126 |
| Investments | 6 | 19 | -0 | 0 | 0 | 0 |
| 57 | 102 | 199 | 289 | 439 | 562 | |
| Total Assets | 131 | 213 | 344 | 514 | 717 | 988 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 10 | 35 | -3 | 66 | 49 | |
| -22 | -40 | -38 | -49 | -79 | |
| 12 | 13 | 51 | -13 | 53 | |
| Net Cash Flow | -0 | 8 | 10 | 4 | 23 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 115 | 135 |
| Inventory Days | 77 | 79 | 104 | 150 | 309 |
| Days Payable | 70 | 79 | 76 | 115 | 145 |
| Cash Conversion Cycle | 97 | 93 | 142 | 151 | 298 |
| Working Capital Days | 46 | 13 | 30 | 99 | 144 |
| ROCE % | 36% | 36% | 36% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
12h - Certificate under Reg 74(5): no demat requests for quarter ended 31 December 2025.
-
Closure of Trading Window
26 Dec - Trading window closed from 1 Jan 2026 until 48 hours after unaudited results for quarter ending 31 Dec 2025.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 25 Dec
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
22 Dec - Audio recording of 22 Dec 2025 earnings call uploaded; transcript to follow; link provided.
- Announcement under Regulation 30 (LODR)-Investor Presentation 21 Dec
Concalls
-
Dec 2025Transcript PPT
Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.